Cannabis Law Report
DECEMBER 18, 2019
Notably, the increase comes after the company recently broke into the European pharma-market after getting green-lighted from the Irish Government to sell its phytocannabinoid-derived “CannEpil” product to epilepsy sufferers. Both products are proprietary medicinal drugs developed internally through MGC’s research and development divisions.
Cannabis Law Report
APRIL 10, 2019
MP Philippa Whitford (representing Central Ayrshire ), a doctor, called for more support for clinical trials so that doctors will be more willing to prescribe medical cannabis products: “That is quite scary for doctors, particularly as if it is an unlicensed drug, they have to sign a form to say that they accept personal liability.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Cannabis Law Report
NOVEMBER 15, 2021
We are looking forward to the completion of the required IND enabling studies and submitting our IND package to the FDA in anticipation of first-in-human trials,” continued Mr. Mack. for its MET for the nasal delivery of cannabidiol (CBD) for the management of epilepsy in children (rare pediatric disease) and adults.
Cannabis Law Report
NOVEMBER 10, 2021
Once completed, it is our intention to immediately submit our IND package to the FDA so that we may begin human trials,” commented Virpax’s Chairman & CEO Anthony P. With today’s announcement, we believe we are well on our way to completing the required IND-enabling studies for Envelta. Forward-Looking Statement.
The Cannigma
DECEMBER 22, 2021
We have autism and epilepsy. We do participate in clinical trials that are initiated by others, and we will have our own clinical trial using terpene formulations in oil. Well, I think that we can build a wonderful booming adult use consumer packaged goods market. We have, I think, eight PhDs.
Cannabis Law Report
JULY 12, 2019
Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. References. 1Alexandra L.
Cannabis Law Report
OCTOBER 17, 2019
Selinger cites software, point-of-sale systems, and packaging as areas that are thriving in the state. Some of the regulatory controls include limits on THC, packaging and labeling requirements, and products that cannot be combined with THC (e.g., Colorado has legalized both recreational and medical use of cannabis.
Expert insights. Personalized for you.
59 
Let's personalize your content